Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a tiny dose of radiation help fight Alzheimer's?

NCT ID NCT03352258

Disease control Sponsor: Valentina Garibotto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested whether a short course of low-dose radiation to the brain could reduce amyloid plaques, a hallmark of Alzheimer's disease. Twenty people with early Alzheimer's and positive amyloid scans were enrolled. Half received radiation over 5 days, while the other half were followed as a comparison group. The goal was to see if the treatment was safe and could lower amyloid buildup on brain scans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
low-dose radiotherapy (radiation to the brain)
What this could lead to
If it works, this could point toward a new way to reduce amyloid plaques in the brain and possibly slow Alzheimer's progression.
What could go wrong
This is a very small pilot study with only 20 people, so results may not apply widely. It's early research, and the treatment may not work or could cause side effects from brain radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Nov 2017

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ability to understand the clinical trial and give an informed consent * Clinical diagnosis of prodromal AD, or mild or moderate AD * Ability to undergo neurocognitive assessment at baseline visit, alone or accompanied by a caregiver * Amyloid PET scan positivity * Ability to follow the 5-days RT regiment, alone or accompanied by a caregiver Exclusion Criteria: * Inclusion in another disease modifying clinical trial * Previous therapeutic brain irradiation * Evidence of vascular cognitive impairment on Magnetic Resonance Imaging (MRI) (Fazekas score \>1 and Wahlund score \>=10/30) * Oncologic disease (excluding skin cancer) active or in remission from less than 5 years * Evidence of substance abuse (alcohol and/or other drugs) with a dependence during the previous 12 months (DSM-IV criteria) * Presence of subdural hygroma's, subdural hematomas or hydrocephalus * Significant psychiatric comorbidity as assessed during the clinical evaluation by the neurologist/geriatrician in charge * Active or recent (within 3 months) cerebral infection/haemorrhage * Immunocompromised status * Prior history of seizure * Dermatological skin disease of the scalp * Women who are pregnant or breast feeding or who intend to become pregnant during the course of the study; * Lack of safe contraception, defined as: female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease

Contacts and locations

Locations

  • Geneva University Hospital

    Geneva, 1211, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.